IconOVir Bio to Present Preclinical Data on Lead Candidate ICVB-1042 at SITC 2022

SAN DIEGO, Calif.--(BUSINESS WIRE)-- IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that it will present preclinical data on ICVB-1042 in three poster presentations at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022), which is being held in Boston, MA and virtually from November 8-12, 2022.

ICVB-1042, IconOVir’s lead product candidate, is a potent, replicative and systemically available OV. In preclinical studies, ICVB-1042 demonstrated superior potency and selectivity compared to wildtype adenovirus (Ad) and other clinical-stage Ad-based oncolytic viruses, with potent lytic replication in cancer cell lines across a broad range of tumor types. IconOVir is developing both intravenous (IV) and intratumoral (IT) formulations of ICVB-1042 and plans to advance into Phase 1 studies evaluating IV-administered ICVB-1042 in solid tumors in the first half of 2023.

Details of the poster presentations are as follows:

Abstract Title: Evaluation of the anti-tumor activity of ICVB-1042, a novel E2F-tumor selective oncolytic virus, selectively targeting tumor cells in an established human glioblastoma mouse model
Abstract Number: 1363
Session Date and Time: Thursday, November 10, 2022, 9:00 a.m. – 9:00 p.m. ET

Abstract Title: Nonclinical characterization of ICVB-1042, a novel E2F-tumor selective oncolytic virus with the potential to treat solid tumors
Abstract Number: 1362
Session Date and Time: Friday, November 11, 2022, 9:00 a.m. – 8:30 p.m. ET

Abstract Title: The chimeric Ad5/Ad34 fiber of ICVB-1042 oncolytic virus requires the CD46 cell surface receptor for efficient tumor entry
Abstract Number: 1216
Session Date and Time: Friday, November 11, 2022, 9:00 a.m. – 8:30 p.m. ET

Each abstract will become available online on the SITC conference website beginning at 8:00 a.m. ET on Monday, November 7, 2022. For additional information, please visit the SITC 37th Annual Meeting website, which is available at https://www.sitcancer.org/2022/home.

About IconOVir

IconOVir is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. IconOVir’s proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O’Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses and provide a personalized therapy for cancer patients. For more information, please visit www.iconovir.com and follow IconOVir on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005103/en/